Results 81 to 90 of about 23,536 (264)

Prevalence of many comorbidities is similar irrespective of the time since HIV diagnosis in persons ageing with HIV who have survived to age 65 years

HIV Medicine, EarlyView.
Abstract Objective To compare the prevalence of comorbidity in persons with HIV ≥65 years of age based on the time from HIV diagnosis. Design Cross‐sectional observational cohort study. Methods Data was collected from 540 participants in the CHANGE HIV (Correlates of Healthy Aging in Geriatric HIV) study, a longitudinal study of HIV in persons aged 65 ...
Alice Zhabokritsky, Leif Erik Lovblom, Brian Boyachuk, Julien Falutz, Marina Klein, Mona Loutfy, Graham Smith, Darrell Tan, Marianne Harris, Sylvia Guillemi, Nisha Adany, Mark Verway, Gord Arbess, Giovanni Guaraldi, Sharon Walmsley   +14 more
wiley   +1 more source

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens

Journal of the International AIDS Society, 2014
An association of persistent low level viremia (LLV) below 500 copies/mL and a higher risk of therapy failure is still point of controversial discussion.
F. Wiesmann, P. Braun, M. Knickmann, H. Knechten   +3 more
semanticscholar   +1 more source

The Association of Pretransplant CD4 Count With Post‐Kidney Transplant Infectious Outcomes Among Persons With HIV

Transplant Infectious Disease, EarlyView.
In this multi‐center study comparing persons with HIV with pre‐kidney transplant CD4 < 350 cells/µL to those with ≥ 350 cells/µL, we found no difference in relative risk of infection in the first year‐post kidney transplant, 5‐year graft survival, and 5‐year overall survival.
Rebecca H. Burns, Sara Booth, Christin Rogers Marks, Christine M. Durand, Jonathan Hand, Maheen Z. Abidi, Maricar Malinis, Brittany Barnaba, Martha Pavlakis, Douglas Krakower, Carolyn D. Alonso, Audrey Le‐Mahajan   +11 more
wiley   +1 more source

Antiviral activity of MIV-150 against HIV isolates harboring distinct NNRTI-associated mutations.

, 2014
Antiviral activity of MIV-150 against HIV isolates harboring distinct NNRTI-associated mutations.
Nina Derby (528107), Ninochka Jean-Pierre (528108), José A. Fernández-Romero (3152097), James Blanchard (215437), Samantha Seidor (233664), Mayla Hsu (233657), Michael J. Piatak Jr (528110), Brandon F. Keele (50342), Melissa Robbiani (51208), Shimin Zhang (65419), Ciby J. Abraham (233661), Larisa Kizima (233659), Noa Krawczyk (528106), Jeffrey D. Lifson (140183), Thomas M. Zydowsky (233667), Agegnehu Gettie (215440), Aixa Rodriguez (233658), Brooke Grasperge (528109), Meropi Aravantinou (51206), Olga Mizenina (49015)   +19 more
core   +1 more source

Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV‐1 Reverse Transcriptase

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
HIV‐1 reverse transcriptase (HIV‐1 RT) is a polymerase enzyme and a key target in HIV‐1 therapy. The discovery of selective HIV‐1 RT inhibitors has highlighted thiazole scaffolds and their derivatives, thiazolidine‐2‐one and thiazolidine‐2,4‐dione, as promising structures for the rational design of novel non‐nucleoside reverse transcriptase inhibitors (
José Arion da Silva Moura, Matheus Vinicius Guimarães de Melo, Diane Regis Santos do Nascimento, Thaynara Paula Warren Bezerra, Mathieu Métifiot, Patricia Recordon‐Pinson, Maira Galdino da Rocha Pitta, Marina Galdino da Rocha Pitta, Michelly Cristiny Pereira, Marie‐Line Andreola   +9 more
wiley   +1 more source

Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation

Nature Structural &Molecular Biology, 2013
Hundreds of structures of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase (RT) have been determined, but only one contains an RNA/DNA hybrid.
M. Lapkouski, Tian Lan, Jennifer T. Miller, S. Le Grice, Wei Yang   +4 more
semanticscholar   +1 more source

Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations

BMC Bioinformatics, 2011
Background Linear regression models are used to quantitatively predict drug resistance, the phenotype, from the HIV-1 viral genotype. As new antiretroviral drugs become available, new resistance pathways emerge and the number of resistance associated ...
Van Houtte Margriet, Lecocq Pierre, Van Craenenbroeck Elke, Van der Borght Koen, Van Kerckhove Barbara, Bacheler Lee, Verbeke Geert, van Vlijmen Herman   +7 more
doaj   +1 more source

Pediatric response to second-line antiretroviral therapy in South Africa. [PDF]

PLoS ONE, 2012
With improved access to pediatric antiretroviral therapy (ART) in resource-limited settings, more children could experience first-line ART treatment failure.We performed a retrospective cohort analysis using electronic medical records from HIV-infected ...
Brian C Zanoni, Henry Sunpath, Margaret E Feeney   +2 more
doaj   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, Volume 13, Issue 59, 23 October 2026.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source

Forest plot of comparison: efavirenz vs other NNRTI added to the background regimen.

, 2015
Forest plot of comparison: efavirenz vs other NNRTI added to the background regimen.
Paweł Kawalec (467764), Andrzej Pilc (467767), Joanna Kryst (467765)   +2 more
core   +1 more source